Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.
#How Has The Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Growth Evolved From 2024 To 2025, And What’s Ahead?#_x000D_
The market for transthyretin amyloid cardiomyopathy (ATTR-CM) treatment has seen a significant uptick in recent years. Projections indicate growth from $10.36 billion in 2024 to $13.32 billion in 2025 with a compound annual growth rate (CAGR) of 28.5%. The expansion in the preceding years can be associated with a growing number of transthyretin amyloid cardiomyopathy cases, an uptick in transthyretin amyloidosis amongst the elderly population, increased awareness amongst healthcare providers and patients, and the development and enhancement of healthcare services._x000D_
_x000D_
The market size for transthyretin amyloid cardiomyopathy (ATTR-CM) treatment is predicted to experience remarkable growth in the approaching years, skyrocketing to $35.93 billion by 2029, growing at a compound annual growth rate (CAGR) of 28.2%. Factors fueling this expansion during the forecast period include the rising incidence of transthyretin amyloidosis, an increase in diagnoses of neuropathic conditions, a growing elderly population, a rising demand for specific medication to treat this rare disorder’s symptoms, and a surge in healthcare needs. Noteworthy trends expected during the forecast period include the emergence of novel diagnostic technologies, the creation of innovative approaches for therapy management, new and targeted treatments for transthyretin amyloidosis, as well as advancements in diagnostic methods, such as cardiac MRI techniques._x000D_
_x000D_
#Download a free sample to assess the report’s scope and structure:#_x000D_
https://www.thebusinessresearchcompany.com/sample.aspx?id=21304&type=smp_x000D_
_x000D_
#What Are the Primary Drivers Supporting the Market Growth of the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market?#_x000D_
The increase in chronic conditions is projected to boost the growth of the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market. Chronic diseases, which are long-term and advance at a gradual pace, often enduring over a year and needing continuous healthcare, are increasingly becoming prevalent. This rise is due to a variety of reasons such as an aging population, inactive lifestyles, unhealthy food habits, a growing obesity epidemic, and exposure to environmental pollutants. Treatments for transthyretin amyloid cardiomyopathy work by stabilizing transthyretin, minimizing amyloid accumulation, enhancing cardiac performance, and easing symptoms to manage related chronic diseases more effectively. For example, as per the World Health Organization, a specialized agency of the United Nations based in Switzerland, in September 2023, out of the 41 million deaths, 74% were due to non-communicable diseases (NCDs) or chronic diseases, annually. Worldwide, cardiovascular diseases claimed 17.9 million lives, cancer caused 9.3 million deaths, chronic respiratory diseases resulted in 4.1 million deaths and diabetes was responsible for 2.0 million fatalities. Consequently, the upswing in chronic illness prevalence is propelling the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market._x000D_
_x000D_
#Which Primary Segments of the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Are Driving Growth and Industry Transformations?#_x000D_
The transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market covered in this report is segmented –_x000D_
_x000D_
1) By Type: Transthyretin Stabilizers, Nonsteroidal Anti-inflammatory Drugs (NSAID), RNAi Therapy, Other Types_x000D_
2) By Indication: Wild type ATTR Amyloidosis, Hereditary ATTR amyloidosis_x000D_
3) By End-Users: Hospitals, Homecare, Specialty Clinics, Other End Users_x000D_
_x000D_
Subsegments:_x000D_
1) By Transthyretin Stabilizers: Tafamidis, Diflunisal_x000D_
2) By Nonsteroidal Anti-inflammatory Drugs (NSAIDs): Aspirin, Ibuprofen, Other NSAIDs_x000D_
3) By RNAi Therapy: Patisiran, Vutrisiran_x000D_
4) By Other Types: Gene Silencing Therapies, Immunotherapy Approaches, Emerging Small Molecule Therapies_x000D_
_x000D_
#Request customized data on this market:#_x000D_
https://www.thebusinessresearchcompany.com/customise?id=21304&type=smp_x000D_
_x000D_
#Which Regions Are Key Players in the Growth of the #What Are the Primary Drivers Supporting the Market Growth of the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market?# Market?#_x000D_
North America was the largest region in the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_
_x000D_
#What Are the Most Significant Market Trends in the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market?#_x000D_
Key players in the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment marketplace are concentrating on the creation of groundbreaking therapies for ATTR-CM, including orally administered prescription medications designed to stabilize transthyretin (TTR) proteins and minimize amyloid fibril accumulation in the heart. Oral prescription drugs, usually in the form of tablets, capsules, or liquid solutions, are those prescribed by healthcare professionals to be ingested orally. For instance, BridgeBio Pharma Inc., a biotech firm based in the United States, got approval from the U.S. Food and Drug Administration in November 2024 for Attruby (acoramidis) which is intended for the treatment of adults suffering from transthyretin amyloid cardiomyopathy (ATTR-CM). This medication works by stabilizing the TTR protein, leading to a decrease in heart-related deaths and hospitalizations. Clinical studies suggest that this treatment is well-tolerated and offers quick benefits by directly addressing the disease’s root cause._x000D_
_x000D_
#View the full report here:#_x000D_
_x000D_
#What Parameters Are Used to Define the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market?#_x000D_
Transthyretin amyloid cardiomyopathy (ATTR-CM) treatment refers to medical therapies and interventions aimed at managing ATTR-CM, a progressive and life-threatening disease caused by the buildup of misfolded transthyretin (TTR) proteins in the heart, leading to restrictive cardiomyopathy and heart failure._x000D_
_x000D_
#Purchase the full report and get a swift delivery:#_x000D_
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21304_x000D_
_x000D_
#About The Business Research Company:#_x000D_
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_
_x000D_
#Get in touch with us:#_x000D_
The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_
Americas +1 3156230293_x000D_
Asia +44 2071930708_x000D_
Europe +44 2071930708_x000D_
Email us at info@tbrc.info_x000D_
_x000D_
#Follow us on:#_x000D_
_x000D_
LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model